Unawareness of the K/DOQITM guidelines for bone and mineral metbolism in predialysis chronic kidney disease: resultas of the «OSERCE» spanish multicenter-study survey
Desconocimiento de las guías K/DOQITM sobre la alteración del metabolismo óseo-mineral asociada a la enfermedad renal crónica no en diálisis: resultados de la encuesta en el estudio multicéntrico español OSERCE
Read
6189
Timeswas read the article
2071
Total PDF
4118
Total HTML
Share statistics
array:21 [ "pii" => "X2013251408004210" "issn" => "20132514" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2008-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2008;28:637-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3102 "formatos" => array:3 [ "EPUB" => 215 "HTML" => 2409 "PDF" => 478 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699508004213" "issn" => "02116995" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2008-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2008;28:637-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5775 "formatos" => array:3 [ "EPUB" => 255 "HTML" => 4973 "PDF" => 547 ] ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Desconocimiento de las guías K/DOQITM sobre la alteración del metabolismo óseo-mineral asociada a la enfermedad renal crónica no en diálisis: resultados de la encuesta en el estudio multicéntrico español OSERCE" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "637" "paginaFinal" => "643" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Unawareness of the K/DOQITM guidelines for bone and mineral metbolism in predialysis chronic kidney disease: resultas of the «OSERCE» spanish multicenter-study survey" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => " grupo de estudio OSERCE de la Sociedad Española de Nefrología, Jordi Bover, Jose Luis Górriz, A.L. Martin De Francisco, Francisco Caravaca, Guillermina Barril, Luis Miguel Molinero" "autores" => array:7 [ 0 => array:1 [ "apellidos" => "grupo de estudio OSERCE de la Sociedad Española de Nefrología" ] 1 => array:2 [ "nombre" => "Jordi" "apellidos" => "Bover" ] 2 => array:2 [ "nombre" => "Jose Luis" "apellidos" => "Górriz" ] 3 => array:2 [ "Iniciales" => "A.L." "apellidos" => "Martin De Francisco" ] 4 => array:2 [ "nombre" => "Francisco" "apellidos" => "Caravaca" ] 5 => array:2 [ "nombre" => "Guillermina" "apellidos" => "Barril" ] 6 => array:2 [ "nombre" => "Luis Miguel" "apellidos" => "Molinero" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251408004210" "doi" => " " "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408004210?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508004213?idApp=UINPBA000064" "url" => "/02116995/0000002800000006/v0_201502091415/X0211699508004213/v0_201502091415/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251408004288" "issn" => "20132514" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2008-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2008;28:645-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3588 "formatos" => array:3 [ "EPUB" => 231 "HTML" => 2806 "PDF" => 551 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Tooth loss in diabetic patients with and without end-stage renal disease and dialysis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "645" "paginaFinal" => "648" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Pérdida de dientes en pacientes diabéticos con y sin insuficiencia renal crónica y diálisis." ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Arnoldo Mondragón Padilla, Estela de la Rosa García, Sandra Cruz Mérida" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Arnoldo" "apellidos" => "Mondragón Padilla" ] 1 => array:2 [ "nombre" => "Estela" "apellidos" => "de la Rosa García" ] 2 => array:2 [ "nombre" => "Sandra" "apellidos" => "Cruz Mérida" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699508004280" "doi" => " " "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508004280?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408004288?idApp=UINPBA000064" "url" => "/20132514/0000002800000006/v0_201502091634/X2013251408004288/v0_201502091634/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251408004229" "issn" => "20132514" "doi" => " " "estado" => "S300" "fechaPublicacion" => "2008-12-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2008;28:633-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4016 "formatos" => array:3 [ "EPUB" => 243 "HTML" => 3240 "PDF" => 533 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "How much should dialysis time be increased when catheters are used?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "633" "paginaFinal" => "636" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Cuánto tiempo es necesario aumentar la prescripción de hemodiálisis con la utilización de catéteres?" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Maduell, Manel Vera, Marta Arias, Néstor Fontseré, Miquel Blasco, Nuria Serra, Eduardo Bergadá, Aleix Cases, Josep M. Campistol" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Francisco" "apellidos" => "Maduell" ] 1 => array:2 [ "nombre" => "Manel" "apellidos" => "Vera" ] 2 => array:2 [ "nombre" => "Marta" "apellidos" => "Arias" ] 3 => array:2 [ "nombre" => "Néstor" "apellidos" => "Fontseré" ] 4 => array:2 [ "nombre" => "Miquel" "apellidos" => "Blasco" ] 5 => array:2 [ "nombre" => "Nuria" "apellidos" => "Serra" ] 6 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Bergadá" ] 7 => array:2 [ "nombre" => "Aleix" "apellidos" => "Cases" ] 8 => array:2 [ "nombre" => "Josep M." "apellidos" => "Campistol" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699508004221" "doi" => " " "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508004221?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408004229?idApp=UINPBA000064" "url" => "/20132514/0000002800000006/v0_201502091634/X2013251408004229/v0_201502091634/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "titulo" => "Unawareness of the K/DOQITM guidelines for bone and mineral metbolism in predialysis chronic kidney disease: resultas of the «OSERCE» spanish multicenter-study survey" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "637" "paginaFinal" => "643" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => " grupo de estudio OSERCE de la Sociedad Española de Nefrología, Jordi Bover, Jose Luis Górriz, A.L. Martin De Francisco, Francisco Caravaca, Guillermina Barril, Luis Miguel Molinero" "autores" => array:7 [ 0 => array:1 [ "apellidos" => "grupo de estudio OSERCE de la Sociedad Española de Nefrología" ] 1 => array:3 [ "nombre" => "Jordi" "apellidos" => "Bover" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:4 [ "nombre" => "Jose Luis" "apellidos" => "Górriz" "email" => array:1 [ 0 => "jlgorriz@ono.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 3 => array:3 [ "Iniciales" => "A.L." "apellidos" => "Martin De Francisco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 4 => array:3 [ "nombre" => "Francisco" "apellidos" => "Caravaca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] ] ] 5 => array:3 [ "nombre" => "Guillermina" "apellidos" => "Barril" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "afff" ] ] ] 6 => array:3 [ "nombre" => "Luis Miguel" "apellidos" => "Molinero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "affg" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => " Fundació Puigvert, Barcelona, Barcelona, España, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 1 => array:3 [ "entidad" => " Hospital Dr. Peset, Valencia, Valencia, España, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 2 => array:3 [ "entidad" => " Hospital Marqués de Valdecilla, Santander, Santander, España, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] 3 => array:3 [ "entidad" => " Hospital Infanta Cristina, Badajoz, Badajoz, España, " "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] 4 => array:3 [ "entidad" => " Hospital de La Princesa, Madrid, Madrid, España, " "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "afff" ] 5 => array:3 [ "entidad" => " Alce Informática, España, " "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "affg" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Desconocimiento de las guías K/DOQITM sobre la alteración del metabolismo óseo-mineral asociada a la enfermedad renal crónica no en diálisis: resultados de la encuesta en el estudio multicéntrico español OSERCE" ] ] "textoCompleto" => "INTRODUCTION <br></br><br></br>After publication of the European guidelines,1 the American National Kidney Foundation published its own clinical practice guidelines (K/DOQITM or Kidney Disease Outcome Quality Initiative) for bone metabolism and disease in chronic kidney disease (CKD) in 2003, which became the worldwide reference used for many years.1 Although they were always disputed because of the high degree of «expert opinion» contained in their recommendations, it is clear that they are not only a worldwide reference but also very popular, well-known and extensively followed in the management of dialysis patients.3-5. However, the condition previously known as «renal osteodystrophy»6 and now generically called chronic kidney disease-mineral and bone disorder7-9 starts long before the need for dialysis,10 and early control of biochemical parameters is also recommended in CKD stages 3-5 predialysis.2 The aim of this <br></br>study was to analyze adherence to the K/DOQITM guidelines for bone and mineral metabolism disorders in patients with CKD stages 3-5 predialysis in a survey of Spanish nephrologists participating in the OSERCE study, three years after publication of the K/DOQITM guidelines. <br></br><br></br>PATIENTS AND METHODS <br></br><br></br>OSERCE is the Spanish acronym for «Epidemiological Study of Bone Disease in Chronic Kidney Disease in Spain». It is was a cross-sectional multicenter study, whose aim was to analyze the clinical and biochemical characteristics <br></br>and the therapeutic management of mineral and bone disorders in CKD (CKD-MBD) in adult patients > 18 years of age with an estimated glomerular filtration rate (GFR) < 60 ml/min/1.73 m2 not yet included in dialysis (CKD stages <br></br>3, 4 and 5). The patients included were from the outpatient clinics of different nephrology department in Spain and <br></br>gave their informed consent to participate in the study. The primary aims of the OSERCE study were to analyze the <br></br>percentage of patients with intact parathyroid hormone (iPTH) levels outside the values recommended by the <br></br>K/DOQITM guidelines,11,12 and to determine the percentage of patients in whom PTH was measured routinely. Each investigator completed a questionnaire before starting the study. The results of this questionnaire are reported in the present paper. <br></br><br></br>Questionnaire <br></br>The study included a questionnaire completed by each investigator/center on their clinical practice in CKD-MBM requesting both the frequency of measurements of bone metabolism parameters (calcium, phosphorus, intact PTH and calcidiol) and the target ranges considered as treatment goals in this population in the different stages of CKD. Practices related to the measurement of plasma bicarbonate and the performance of imaging tests to assess the presence of calcifications were also analyzed. The study was carried out from April to May 2006 and completed in 32 centers. <br></br><br></br>We considered «inadequate» responses as those outside the ranges recommended in the K/DOQITM clinical practice guidelines for CKD patients not on dialysis and shown in table I. Hypercalcemia was defined as corrected calcium values exceeding 10.2 mg/dl in accordance with the guidelines.2 <br></br><br></br>The results are expressed as the mean (mean percentage) and 95% confidence intervals (CI) (95% CI, lower limitupper limit). <br></br><br></br>RESULTS <br></br>The questionnaires were answered by the 32 investigators participating in the OSERCE study, all of whom were nephrologists treating patients with CKD not on dialysis. The polled nephrologists were 16 women and 16 men with a mean age of 44.6 ± 9.1 years, median age of 44 years (range: 27-60) (95% CI: 41-48), and a mean of 17 ± 6 years working in nephrology (95% CI: 14-21). <br></br><br></br>Frequency of measurement of recommended biochemical parameters <br></br>Table II shows the frequency of measurement of the most important biochemical parameters and their comparison with the follow-up recommended by the K/DOQITM guidelines.2 As much as 87.5% of polled nephrologists stated that they did not systematically measure calcidiol plasma levels despite of these recommendations. Among polled nephrologists, 50% never performed this measurement (95% CI, 33-66), 37.5% performed it sometimes (95% CI, 22-54) and only five investigators (12.5%) always performed it (95% CI, 5-29). <br></br><br></br>Treatment goals for iPTH, calcium, phosphorus and calcium-phosphorus product <br></br>Tables III, IV, V and VI show the percentage reported as the treatment goal for plasma levels of intact PTH, phosphorus, calcium and calcium x phosphorus product, respectively. Table 3 shows that treatment goals for intact PTH were adequately reported for patients in stage 3 by only 41% of polled nephrologists (95% CI, 24-57). They were adequately reported by 36% (95% CI, 21-54) in stage 4 and by 78% (95% CI, 59-89) in stage 5. <br></br><br></br>Table IV shows that treatment goals for plasma phosphorus were adequately reported only in 50% of patients in stage 3 (95% CI, 33-67) and 50% in stage 4 (95% CI, 33-67), and in 53% of patients in stage 5 (95% CI, 36-69). The most frequent discrepancy was to consider adequate phosphorus levels between 3.5 and 5.5 mg/dl in stages 3 and 4, which are usually recommended in stage 5 in dialysis patients. Table V shows that treatment goals for calcium were inadequately reported by only 30-35% of polled nephrologists, but goals between 9.5 and 10.2 mg/dl were still considered adequate in 31% of the responses (95% CI, 17-49). Hypercalcemia was defined as corrected calcium levels greater than 9.5, 10.2 and 10.5 mg/dl by 10% (95% CI, 4-26), 52% (95% CI, 35-68) and 38% (95% CI, 23-56) of nephrologists, respectively. Table V shows that at least 90% of polled nephrologists was knowledgeable of the recommended values for the Ca x P product (< 55 mg/dl) in the different stages of CKD. <br></br><br></br>Other aspects of the questionnaire <br></br>We finally note that 93% of polled nephrologists stated that they did not regularly measure bicarbonate levels (95% CI, 78-98). A target level of 22-25 mEq/l was considered adequate by 76% (95% CI, 58-87), 17% (95% CI, 8-34) accepted a certain degree of acidosis (18-21 mEq/l) and the rest considered adequate levels between 26-28 mEq/l. In addition, 72% of nephrologists (95% CI, 54-85) performed imaging tests to evaluate the presence of calcifications (mainly plain chest or abdominal X-rays or echocardiograms in approximately 50% of cases), while bone densitometry was performed in 39% of cases (95% CI, 24-57). <br></br><br></br>DISCUSSION <br></br><br></br>Although the European guidelines were published previously, 1 the American National Kidney Foundation published <br></br>shortly afterwards its own K/DOQITM clinical practice guidelines for bone metabolism and disease in CKD.2 It was <br></br>also in these same K/DOQITM guidelines that the current concept of CKD was first defined, and which has been recently adopted with minor changes by the KDIGO (Kidney Disease Improving Global Outcomes) international initiative.13,14 It is clear that the K/DOQITM guidelines have become the worldwide reference used in most countries and studies, and they were a common standard of definitions and treatment goals for many years.  Although the guidelines for bone metabolism and disease were always disputed because of the high degree of «expert opinion» contained in their recommendations,2 it is clear that they have been a unifying element that has permitted all nephrologists to use the same language and to compare uniformly the results of different studies, and thus they have been very popular, well-known and extensively followed in the management of dialysis patients.3-5 <br></br><br></br>Recently, and coinciding with the growing importance of early diagnosis of CKD and cardiovascular risk factors associated with CKD in clinical practice,13-19 several articles have demonstrated the association between mortality and serum levels of different biochemical parameters related to mineral metabolism.20-22 So much so that the KDIGO international guidelines have introduced a new broader concept (CKD-MBD, or Chronic Kidney Disease-Mineral and Bone Disorder) which emphasizes the importance of control of bone and mineral disorders associated with CKD beyond mere control of bone disease to achieve a systemic dimension,7 but only a draft version for discussion showing their guidelines in this area has been published. It is for this reason that the K/DOQITM guidelines are still the worldwide reference, especially in dialysis patients, at least until forthcoming publication of the next version of the KDIGO guidelines. <br></br><br></br>However, CKD-MBD starts long before the need for dialysis, 10,23,24 so the K/DOQITM guidelines also included target recommendations for predialysis CKD patients.2 In this study, it can be clearly seen that the degree of knowledge of predialysis guidelines is very poor among the Spanish nephrologists working in the outpatient clinics of the different centers participating in the OSERCE study. <br></br><br></br>First, it is notable that the different biochemical parameters were measured less frequently than recommended by current guidelines except in patients with CKD stage 3 and measurement of intact PTH in patients with CKD stage 5. Intact PTH was measured more frequently in patients in stage 3 (PTH was measured yearly in about 30% of patients and two or more times a year in up to 70%) and in stage 5, where PTH was measured in 83% of patients with equal or greater frequency than recommended (33% of patients even had monthly measurement of intact PTH). This frequency was even higher for calcium and phosphorus in patients in stage 3, where more than 90% of patients had measurements in periods of less than 6 months. Obviously, it is well known that stage 3 encompasses a heterogeneous group of patients with kidney function ranging from the upper limit of the definition of CKD (60 ml/min/1.73 m2) to glomerular filtration rates of 30 ml/min/1.73 m2. Some have thus considered it appropriate to divide stage 3 in stage 3A (< 60-45 ml/min/1.73 m2) and 3B (< 45-30 ml/min/1.73 m2) to make this population more homogeneous for follow-up, referral to the specialist or even different therapeutic management.17,25 It is then likely that this frequency of measurement will better match the real needs of these patients than the lax recommendation of the K/DOQITM guidelines. In contrast, calcium and phosphorus levels were measured less frequently than recommended by current guidelines in CKD stages 4 and 5, probably better reflecting not only the different care realities, but also, especially in stage 5, the lack of division of stage 5 between patients on dialysis <br></br>(current stage 5D where monthly measurement of patients is logistically feasible) and those who glomerular filtration rate is < 15 ml/min/1.73 m2, but who are not yet in a dialysis program. <br></br><br></br>It is also notable that 87% of nephrologists did not measure systematically calcidiol levels in their predialysis patients despite the fact that measurement of calcidiol has been recommended since the implementation of the K/DOQITM guidelines, at least for management of hyperparathyroidism in patients with CKD stages 3 and 4.2 This fact has particular relevance if we consider that CKD patients frequently have vitamin D deficiency or insufficiency, sometimes severe,11,23,24 even in our setting,11,24 and that vitamin D is attributed multiple pleiotropic effects and effects on survival that go beyond bone metabolism.26,27 In addition, different vitamin D receptor activators can have different effects on survival.28 In Spain, the easy availability of cholecalciferol or ergocalciferol in the <br></br>required doses, as well as the lack of comparative analyses between active forms and native vitamin D has no doubt influenced this observation. Only recently has an article appeared on an observation study analyzing the relationship between differences in early survival in dialysis patients and plasma vitamin D levels in patients treated or not with active forms of vitamin D.29 <br></br><br></br>Of note regarding the K/DOQITM guidelines was the extensive knowledge of treatment goals for PTH in stage 5, where 78% of polled nephrologists had target PTH values between 150-300 pg/ml considered with a grade of evidence in the K/DOQITM guidelines,2 although currently questioned.8,30 In stages 3 and 4, only approximately 40% (36-41%) of nephrologists had the treatment goal for PTH recommended in the guidelines. This observation is important in that different studies have determined the difficulty in complying with K/DOQITM guidelines and the need for new drugs to achieve treatment goals both in patients on dialysis4,31,32 and in predialysis,12,24,33,34,35 <br></br>but our results provide the new information that not only is there a lack of approved and effective therapeutic agents in predialysis, but also a high degree of unawareness or disbelief of current recommendations. In fact, it can be seen in the analysis of the responses that the most frequent bias was to consider normal in stages 3 and 4 values that are more widely known and which are recommended in the K/DOQITM guidelines for patients in stage 5 on dialysis (for example, phosphorus levels of 3.5-5.5 mg/dl). Strictly inadequate plasma calcium levels were reported by less than 4% of nephrologists. However , there was still nearly 30% of nephrologists whose treatment goal was calcium levels between 9.5-10.2 mg/dl (the limit between desirable calcium and the definition of  hypercalcemia is poorly defined in the K/DOQITM guidelines). Similarly, 38% of polled nephrologists considered hypercalcemia as values > 10.5 mg/dl, whereas only 10% defined hypercalcemia as values > 9.5 mg/dl, thus still reflecting the treatment trends maintained until not long ago.6,36 This finding has recently been documented in the distribution of the results of the DOPPS (Dialysis Outcomes and Practice Patterns Study), where it can be seen that Spain, Germany and Sweden were the only countries in which plasma calcium did not decrease significantly in dialysis patients during its different phases (covering from 1996 to the present).37 Curiously, 90% of nephrologists were knowledgeable of Ca x P recommended values, despite the fact that it is probably the least precise parameter <br></br>in control of mineral metabolism, especially in predialysis. 12 <br></br><br></br>It is notable the high percentage of follow-up reported for bicarbonate levels in patients with CKD. Although the bicarbonate levels recommended by the guidelines are clearly defined as greater than or equal to 22 mEq/L, 17% of polled nephrologists accept a slight degree of acidosis. In view of current knowledge, it is likely that the degree of control of acidosis will require revision in the near future.38,39 Finally, it is worth mentioning that a large percentage of nephrologists (72%) uses imaging tests to search for vascular calcification in the diagnosis of CKD-MBD,7 generally tests of low complexity. However, although bone densitometry is not recommended in patients with CKD,7 it is still used by 39% of nephrologists participating in this study. <br></br><br></br>Our study has several limitations, all related to the relatively small number of nephrologists who completed the questionnaire and the validity that can be given to the results of a questionnaire. To add a measurement of precision, the percentages are accompanied by their respective 95% confidence intervals. Nevertheless, the participants were professionals dedicated especially to CKD not on dialysis or predialysis units. In any case, the results obtained could have shown an even lower degree of knowledge of the K/DOQITM guidelines if nephrologists dedicated to other areas of nephrology had been surveyed. The surveys were conducted in nephrologists from all areas of the Spanish territory, and although random sampling was not performed for selection of participants because the number of CKD or predialysis units is not significantly higher than that included, the data might be representative of the CKD population in Spain. Nevertheless, and with the consequent limitations, the information obtained is of great importance for knowing clinical practices in CKD-MBD. <br></br><br></br>In summary, these results demonstrate that there is a great degree of unawareness of K/DOQITM predialysis guidelines. Thus, their poor implementation is probably not only due to the lower availability of approved therapeutic agents, but also to unawareness or disbelief of current recommendations. It would be desirable that the recently published new guidelines of the Spanish Society of Nephrology8 or forthcoming international guidelines include not only well-defined information on predialysis patients but also educational efforts on the need for early diagnosis and treatment of CKD-MBD. <br></br>" "pdfFichero" => "P-E-S-A335-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:10 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440497" "palabras" => array:1 [ 0 => "PTH" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440499" "palabras" => array:1 [ 0 => "CKD-MBD" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440501" "palabras" => array:1 [ 0 => "Metabolismo mineral" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440503" "palabras" => array:1 [ 0 => "Enfermedad renal crónica" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440505" "palabras" => array:1 [ 0 => "K/DOQI" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440507" "palabras" => array:1 [ 0 => "Guías" ] ] 6 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440509" "palabras" => array:1 [ 0 => "Osteodistrofia" ] ] 7 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440511" "palabras" => array:1 [ 0 => "Fósforo" ] ] 8 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440513" "palabras" => array:1 [ 0 => "Vitamina D" ] ] 9 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440515" "palabras" => array:1 [ 0 => "Calcificación" ] ] ] "en" => array:10 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440498" "palabras" => array:1 [ 0 => "PTH" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440500" "palabras" => array:1 [ 0 => "CKD-MDB" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440502" "palabras" => array:1 [ 0 => "Mineral metabolism" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440504" "palabras" => array:1 [ 0 => "Chronic kidney disease" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440506" "palabras" => array:1 [ 0 => "K/DOQI" ] ] 5 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440510" "palabras" => array:1 [ 0 => "Osteodystrophy" ] ] 6 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440512" "palabras" => array:1 [ 0 => "Phosphorous" ] ] 7 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440514" "palabras" => array:1 [ 0 => "Vitamin D" ] ] 8 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440508" "palabras" => array:1 [ 0 => "Guidelines" ] ] 9 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440516" "palabras" => array:1 [ 0 => "Calcification" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "RESUMEN Desde su publicación en el 2003, las guías K/DOQITM sobre metabolismo y enfermedad ósea en la enfermedad renal crónica (ERC) han sido referencia internacional. El objetivo de este estudio fue analizar el grado de conocimiento de las mismas en pacientes con ERC estadios 3, 4 y 5 no en diálisis mediante una encuesta a 32 nefrólogos españoles que participaron en el estudio OSERCE. De este análisis se deduce que la frecuencia teórica de medición de parámetros bioquímicos es habitualmente menor a la recomendada, excepto en el estadio 3. Los objetivos terapéuticos para la PTH intacta fueron inadecuadamente reportados por el 59% de los nefrólogos encuestados para estadios 3 y 4, mientras que para el estadio 5 sólo por el 22%. Los objetivos para el fósforo fueron inadecuadamente reportados en el 50 % de los casos (estadios 3 y 4) y 60% (estadio 5). Para el calcio fueron del 70%, 73,3% y 65,5% en los estadios 3, 4 y 5 respectivamente. Un calcio plasmático corregido entre 9,5 y 10,2 mg/dl fue todavía considerado apropiado en el 31% de las respuestas. Hasta un 87% de los nefrólogos consultados manifestaron no medir sistemáticamente los niveles plasmáticos de calcidiol. En general, estos resultados demuestran que existe un alto grado de desconocimiento de las guías K/DOQITM en los pacientes con ERC no en diálisis. Por consiguiente, la falta de implementación de las mismas no sólo ha sido debido a la menor disponibilidad de agentes terapéuticos prediálisis, la dificultad de cumplimiento de objetivos o la propia incertidumbre de las guías sino también a su desconocimiento. Sería pues recomendable que próximas guías como las K-DIGO vinieran acompañadas también de intervenciones de carácter educativo en el diagnóstico y tratamiento precoz de las alteraciones del metabolismo óseo-mineral asociado a la ERC." ] "en" => array:1 [ "resumen" => "SUMMARY Since its publication in 2003, the K/DOQITM clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) have become a worldwide reference. The aim of this study was to analyze the observance to these guidelines in patients with a glomerular filtration rate < 60 ml/min/1.73m2 not yet included in dialysis in a Spanish multicenter cohort. A questionnaire by investigator/ centre was completed by 32 different nephrologists participating in the OSERCE study and representing the overall Spanish public health net. We observed that biochemical parameters were measured less frequently than recommended, except in CKD stage 3. The therapeutic goals for intact PTH were not properly reported by 59% of the consulted nephrologists for stages 3 and 4, whereas only 22% did not report them properly for stage 5. The goals for phosphorus were not adequately reported in 50% of cases (stages 3 y 4) and 60% (stage 5). For calcium, these values were 70 %, 73.3% and 65.5% for stages 3, 4 and 5, respectively. A corrected plasma calcium between 9.5 and 10.2 mg/dl is still considered adequate for 31%. As much as 87% nephrologists stated that they did not sistematically measure calcidiol plasma levels. In general, these results demonstrate that there is a great degree of unawareness of K/DOQITM predialysis guidelines. Thus, their poor implementation is probably not only due to the lower availability of approved therapeutic agents, the difficult achievement of goals or the disbelief on current recommendations. It would be desirable that forthcoming guidelines such as the KDIGO could also consider the need of educational efforts for CKD-Mineral and Bone Disorder." ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:39 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "5.- BIBLIOGRAFIA" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "1) Cannata-Andía JB for the Medical Working Group: Clinical algorithms on renal osteodystrophy. Nephrol Dial Transplant 15 (Supl 5):S-43, 2000." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "2) National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (4 Suppl 3):S1-201, 2003. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14520607" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "3) Moe S, Chertow GM, Coburn JW, Quarles D, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQITM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney International 67:760-771, 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15673327" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "4) Arenas MD, Alvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Núñez C, Devesa R, Albiach B. Consequences of the implementation of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease in a population of patients on chronic hemodialysis. J Nephrol 20 (4):453-461, 2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17879212" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "5) Bover J, Ballarín J, Andrés E, Ortiz-Herbener F, Barceló P. New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcimimetics. Nefrologia 25 (Suppl 2):109-116; 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16050413" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "6) F. Llach y J Bover. Renal Osteodystrophies. En The Kidney. 6ª Edición. Brenner B.M. (editor). W.B. Saunders Company , p 2103-2186, 2000." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "7) Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease:Improving Global Outcomes (KDIGO). Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int 69 (11):1945-1953, 2006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16641930" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "8) Torregrosa JV, Cannata J, Bover J, Caravaca F, Lorenzo V, de Francisco ALM, Martín-Malo A, Martínez I, González-Parra E, Fernández E, Rodríguez M. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica. Nefrologia 28 (Supl 1): 1-22, 2008-05-27" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "9) Bover J, Canal C, Marco H, Fernández-Llama P, Bosch RJ, Ballarín J. Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. Contrib Nephrol 161:222-233, 2008" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "10) Martínez I, Saracho R, Montenegro J, Llach J. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29 (4):496-502, 1997" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "11) Górriz JL, Bover J, Caravaca F, Barril G, Molinero LM, de Francisco AM, Oserce Study Group. ¿OSERCE¿ Multicenter Spanish Study: vitamin D levels in CKD stages 3-5 predialysis. Nephrol Dial Transplant 22 (Suppl 6): vi173, 2007 (abstract)" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "12) Bover J, Górriz JL, Caravaca F, Barril G, Molinero LM, de Francisco AM, Oserce Study Group. ¿OSERCE¿ Multicenter Spanish Study: insufficient adherence to CKD-mineral-bone-disorder guidelines in stages 3-5 predialysis. Nephrol Dial Transplant 22 (Suppl 6): vi174, 2007 (abstract)" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "13) Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, clssification and stratification. Ann Int Med 139 (2):137-147, 2003" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "14) Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (6): 2089-2100, 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15882252" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "15) Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108(17):2154-69, 2003." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "16) Gracia S, Montañes R, Bover J, Cases A, Deulofeu R, de Francisco ALM, Orte LM. Documento de consenso: Recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. Nefrologia 26(6):658-65, 2006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17227242" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "17) Canal C, Pellicer R, Rocha CI, Calero F, Gracia S, Montañés R, Ballarín J, Bover J. Tablas para la estimación del filtrado glomerular a partir de la creatinina plasmática. Nefrologia 28 (3):1-7, 2008" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "18) Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic Kidney Disease and the risks of death, cardiovascular events and hospitalization. New Eng J Med 351 (13):1296-1305, 2004" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "19) Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Int Med 164 (6):659-663, 2004." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "20) Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (8):2208-2218, 2004. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15284307" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "21) Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (4):771-780, 2006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16820797" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "22) Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (3):1179-1187, 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15698460" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "23) Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 (1):31-38, 2007" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "24) Craver L, Marco MP, Martínez I, Rue M, Borrás M, Martín ML, Sarró F, Valdivielso JM, Fernández E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5¿achievement of K/DOQI target ranges. Nephrol Dial Transplant 22 (4): 1171-1176, 2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17205962" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "25) Barlett AG, Brown A, Christie B, Elliott A, Griffith K, Pound S, Rappaport I, Robertson D, Semple Y, Slane P, Whitworth C, Williams B. UK consensus conference on early Chronic Kidney Disease. Nephrol Dial Transplant 22 (Suppl 9):ix4-ix5, 2007." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "26) Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16 (4):1115-1125, 2005. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15728786" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "27) Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Int Med 168 (4):397-403, 2008." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "28) Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Eng J Med 349 (5): 446-456, 2003. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12890843" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "29) Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, Thadhani R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72 (8):1004-1013, 2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17687259" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "30) Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer study group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19 (2):405-412, 2008. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18199805" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "31) Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Núñez C, Devesa R, Carretón MA, Soriano A. Implementation of K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 22 (6):1639-1644, 2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17277339" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "32) Cozzolino M, Brancaccio D. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. Int J Artif Organs 30 (4):293-300, 2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17520565" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "33) Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3: 1125-1130. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18450923" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "34) Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47 (2):263-276, 2006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16431255" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "35) Barril G, Sanz P, Bardón E, Andrino T, Cigarrán S, Díaz A, Selgas R. Valoración de parámetros de osteodistrofia en una unidad de prediálisis. Nefrologia 2003; 23 (Supl. 2): 43. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12778853" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "36) Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked supression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74 (6):2136-2143, 1984. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6549016" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "37) Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Azikawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH. The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52 (3): 519-530, 2008" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S0021915013001743" "estado" => "S300" "issn" => "00219150" ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "38) Bommer J, Locatelli F, Satayathum S, Keen ML, Goodkin DA, Saito A, Akiba T, Port FK, Young EW. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (4):661-671, 2004. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15384017" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000002800000006/v0_201502091634/X2013251408004210/v0_201502091634/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002800000006/v0_201502091634/X2013251408004210/v0_201502091634/en/P-E-S-A335-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408004210?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 8 | 12 | 20 |
| 2024 October | 42 | 36 | 78 |
| 2024 September | 43 | 40 | 83 |
| 2024 August | 47 | 72 | 119 |
| 2024 July | 29 | 30 | 59 |
| 2024 June | 48 | 36 | 84 |
| 2024 May | 45 | 32 | 77 |
| 2024 April | 36 | 35 | 71 |
| 2024 March | 34 | 19 | 53 |
| 2024 February | 28 | 37 | 65 |
| 2024 January | 25 | 25 | 50 |
| 2023 December | 23 | 26 | 49 |
| 2023 November | 32 | 33 | 65 |
| 2023 October | 36 | 38 | 74 |
| 2023 September | 27 | 23 | 50 |
| 2023 August | 30 | 28 | 58 |
| 2023 July | 28 | 35 | 63 |
| 2023 June | 35 | 19 | 54 |
| 2023 May | 23 | 22 | 45 |
| 2023 April | 23 | 19 | 42 |
| 2023 March | 30 | 18 | 48 |
| 2023 February | 40 | 24 | 64 |
| 2023 January | 22 | 23 | 45 |
| 2022 December | 45 | 33 | 78 |
| 2022 November | 36 | 14 | 50 |
| 2022 October | 31 | 45 | 76 |
| 2022 September | 45 | 30 | 75 |
| 2022 August | 42 | 41 | 83 |
| 2022 July | 22 | 36 | 58 |
| 2022 June | 34 | 28 | 62 |
| 2022 May | 22 | 33 | 55 |
| 2022 April | 26 | 27 | 53 |
| 2022 March | 36 | 50 | 86 |
| 2022 February | 31 | 43 | 74 |
| 2022 January | 28 | 39 | 67 |
| 2021 December | 34 | 43 | 77 |
| 2021 November | 24 | 31 | 55 |
| 2021 October | 30 | 52 | 82 |
| 2021 September | 32 | 37 | 69 |
| 2021 August | 23 | 27 | 50 |
| 2021 July | 26 | 29 | 55 |
| 2021 June | 21 | 22 | 43 |
| 2021 May | 25 | 35 | 60 |
| 2021 April | 59 | 41 | 100 |
| 2021 March | 33 | 20 | 53 |
| 2021 February | 24 | 14 | 38 |
| 2021 January | 21 | 16 | 37 |
| 2020 December | 25 | 9 | 34 |
| 2020 November | 29 | 20 | 49 |
| 2020 October | 17 | 16 | 33 |
| 2020 September | 22 | 8 | 30 |
| 2020 August | 28 | 7 | 35 |
| 2020 July | 19 | 8 | 27 |
| 2020 June | 14 | 18 | 32 |
| 2020 May | 18 | 10 | 28 |
| 2020 April | 30 | 11 | 41 |
| 2020 March | 16 | 14 | 30 |
| 2020 February | 18 | 14 | 32 |
| 2020 January | 30 | 21 | 51 |
| 2019 December | 30 | 19 | 49 |
| 2019 November | 28 | 20 | 48 |
| 2019 October | 20 | 10 | 30 |
| 2019 September | 18 | 11 | 29 |
| 2019 August | 13 | 13 | 26 |
| 2019 July | 19 | 21 | 40 |
| 2019 June | 14 | 7 | 21 |
| 2019 May | 11 | 10 | 21 |
| 2019 April | 27 | 22 | 49 |
| 2019 March | 15 | 13 | 28 |
| 2019 February | 12 | 12 | 24 |
| 2019 January | 13 | 13 | 26 |
| 2018 December | 40 | 23 | 63 |
| 2018 November | 57 | 10 | 67 |
| 2018 October | 61 | 9 | 70 |
| 2018 September | 29 | 12 | 41 |
| 2018 August | 28 | 8 | 36 |
| 2018 July | 27 | 12 | 39 |
| 2018 June | 20 | 7 | 27 |
| 2018 May | 30 | 12 | 42 |
| 2018 April | 37 | 9 | 46 |
| 2018 March | 27 | 15 | 42 |
| 2018 February | 35 | 6 | 41 |
| 2018 January | 23 | 9 | 32 |
| 2017 December | 48 | 10 | 58 |
| 2017 November | 20 | 3 | 23 |
| 2017 October | 35 | 9 | 44 |
| 2017 September | 17 | 10 | 27 |
| 2017 August | 19 | 9 | 28 |
| 2017 July | 26 | 13 | 39 |
| 2017 June | 11 | 3 | 14 |
| 2017 May | 18 | 9 | 27 |
| 2017 April | 17 | 13 | 30 |
| 2017 March | 15 | 8 | 23 |
| 2017 February | 18 | 5 | 23 |
| 2017 January | 7 | 7 | 14 |
| 2016 December | 30 | 5 | 35 |
| 2016 November | 22 | 11 | 33 |
| 2016 October | 34 | 6 | 40 |
| 2016 September | 71 | 6 | 77 |
| 2016 August | 185 | 6 | 191 |
| 2016 July | 120 | 11 | 131 |
| 2016 June | 95 | 0 | 95 |
| 2016 May | 105 | 0 | 105 |
| 2016 April | 75 | 0 | 75 |
| 2016 March | 65 | 0 | 65 |
| 2016 February | 79 | 0 | 79 |
| 2016 January | 85 | 0 | 85 |
| 2015 December | 87 | 0 | 87 |
| 2015 November | 77 | 0 | 77 |
| 2015 October | 81 | 0 | 81 |
| 2015 September | 50 | 0 | 50 |
| 2015 August | 84 | 0 | 84 |
| 2015 July | 59 | 0 | 59 |
| 2015 June | 34 | 0 | 34 |
| 2015 May | 39 | 0 | 39 |
| 2015 April | 6 | 0 | 6 |
Show all
